

APPENDIX H



Keep As New

Delete

1 of 5

Next

Subj: Trans.: Additive of Krill
From: [Richard Biocean](#)
To: [MBoud1409](#)

Richard Boudreault

Subject: Additive of Krill
Date: Wed, 24 Apr 2002 21:29:57 -0700
From: "Y. Akai" <cel@conspac.com>
To: Belanger <andreb@neptunebiotech.com>
Cc: Boudreault <RichardBiocean@aol.com>

Dear Mr. Belanger:

This is to confirm that the chemical added to krill is "sodium hydrogen sulfite" whose chemical symbols are "NaHSO3". This is the only additive that is added to krill and its purpose is not for anti-oxydant nor anti-enzyme.

The amount of this additive in krill is approximately 100 ppm, but this is the target amount, so actually a little bit more may be added.

I hope this information will help you make a decision quickly.

Regards,

Yas Akai
Conspac/Nippon Suisan

Keep As New

Delete

1 of 5

Next

Help

☐ Include original text in reply.



500, boul. Saint-Martin Ouest
Bureau 550
Laval (Québec)
Canada H7M 3Y2

Téléphone : (450) 972-6291
Sans frais : 1 888 664-9166
Télécopieur : (450) 972-6351
www.neptunebiotech.com

Division of Standards and Labeling Regulations
Office of Nutritional Products, Labeling, and Dietary Supplements (HFS-820)
Center for Food Safety and Applied Nutrition
Food and Drug Administration
200 C Street, SW
Washington, DC 20204
Telephone Number: (202) 205-4168

February 17, 2002

Please find enclosed a pre-market notification information package including:

1. Neptune Technologies & Bioressources Inc. (Executive Summary)
2. General information on primary source (raw material)
3. Neptune product description
4. Research protocols
5. Literature review relevant to the components of Neptune products

Even though the components of our products individually are not "new ingredients" the combination of these components as well as the source is "new" in the USA dietary supplement market. My aim is to maintain excellent compliance with FDA & DSHEA Regulations. Consequently, I would like to take the opportunity to inform you of the product and request your comments and further guidance in order to obtain pre-market approval for the import and sale of these products in the USA.


Please note that the specified information is regarded as highly confidential and should not be distributed.

Please feel free to contact me for any further information you may require. My coordinates are:

Tina Sampalis M.D., Ph.D.
Vice-President of Research
Neptune Technologies & Bioressources Inc.
500 St. Martin Blvd. West
Laval, Québec
H7W 3J8, Canada
Tel. 450-972-6291
Fax. 450-972-6351
E-Mail: tinas@neptunebiotech.com

Sincerely

Tina Sampalis M.D., Ph.D.
Vice-President of Research



79407

**PRE-MARKET NOTIFICATION
INFORMATION PACKAGE**

**NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
DEPARTMENT OF RESEARCH**

Tina Sampalis M.D., Ph.D.

February 17, 2002

Table of Contents

1. Company Profile / Executive Summary
2. General Information on Primary Source (Krill - *Euphausia Superba*)
3. Product Description
 - a. Neptune Krill Oil™
 - b. Neptune Aquateine™
 - c. Neptune Lyo-Krill™
4. Product Safety
5. Medical Research
 - a. Preclinical Trial Protocols
 - i. UVB-induced skin cancer
 - ii. Transdermal transport
 - b. Clinical Trials
Investigator's brochure
 - i. Cardiovascular disease
 - a. Trial protocol
 - b. Patient consent form
 - c. Clinical trial attestation
 - ii. Rheumatoid arthritis
 - a. Trial protocol
 - b. Patient consent form
 - c. Clinical trial attestation
 - iii. Facial wrinkles
 - a. Trial protocol
 - b. Patient consent form
 - c. Clinical trial attestation
6. Literature review relevant to the components of Neptune products
 - a. Krill
 - b. Cardiovascular disease
 - c. Inflammatory disease
 - d. Phospholipids
 - e. Astaxanthin